PMLT21059 / APEC1621H / Angela GirvinResearch Question:
Basic Study Information
Purpose:Location: University of Rochester
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients
with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in
deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in
the body (advanced) and have come back (relapsed) or do not respond to treatment (refractory).
Olaparib is an inhibitor of PARP, an enzyme that helps repair DNA when it becomes
damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA,
causing them to die. PARP inhibitors are a type of targeted therapy.
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search